| CTRI Number |
CTRI/2022/12/047809 [Registered on: 01/12/2022] Trial Registered Prospectively |
| Last Modified On: |
17/04/2023 |
| Post Graduate Thesis |
No |
| Type of Trial |
Interventional |
|
Type of Study
|
Nutraceutical |
| Study Design |
Randomized, Parallel Group, Placebo Controlled Trial |
|
Public Title of Study
|
A clinical study of nutritional and phytoconstituents supplementation in prediabetic subjects |
|
Scientific Title of Study
|
A Randomized, placebo controlled study to assess the efficacy & safety of nutritional and phytoconstituents supplementation in prediabetic subjects |
| Trial Acronym |
Nil |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| MHC/CT/22-23//007 Version: 1.00 dated 05 Nov 2022 |
Protocol Number |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Shashank Joshi |
| Designation |
Senior consultant |
| Affiliation |
Joshi Clinic |
| Address |
Number twelve,first Floor, Golden Palace, Turner Road, Bandra West, behind
Union Bank, Mumbai
Mumbai MAHARASHTRA 400050 India |
| Phone |
9820186302 |
| Fax |
- |
| Email |
shashank.sr@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Rumaiza Mamsa |
| Designation |
Medical services |
| Affiliation |
Meyer Organics Pvt. Ltd. |
| Address |
First floor, Medical service department , A 303 Road No 32 Wagle Estate Thane Mumbai
Mumbai MAHARASHTRA 400604 India |
| Phone |
9167846090 |
| Fax |
9162757002 |
| Email |
rmamsa@meyer.co.in |
|
Details of Contact Person Public Query
|
| Name |
Neepa Gaba |
| Designation |
Scientific coordinator |
| Affiliation |
Meyer Organics Pvt. Ltd. |
| Address |
First floor, Medical service department , A 303 Road No 32 Wagle Estate Thane Mumbai
Mumbai MAHARASHTRA 400 604 India |
| Phone |
912225817126 |
| Fax |
9162757002 |
| Email |
ngaba@meyer.co.in |
|
|
Source of Monetary or Material Support
|
| Meyer Organics Pvt Ltd A-303, Road No. 32, Wagle Estate, Thane Mumbai Maharashtra 400
604 India |
|
|
Primary Sponsor
|
| Name |
Meyer Organics Pvt Ltd |
| Address |
A-303, Road No. 32, Wagle Estate, Thane Mumbai Maharashtra 400
604 India |
| Type of Sponsor |
Pharmaceutical industry-Indian |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
Sites of Study
Modification(s)
|
| No of Sites = 3 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Jothydev Kesavadev |
Jothydevs Diabetes Research Centre |
JDC Junction, Konkalam Road, Mudavanmugal Poojappura Trivandrum, Kerala, India- 695032 Thiruvananthapuram KERALA |
9895040055 - jothydev@gmail.com |
| Dr V G Vaidya |
Lokmanya Medical Research Centre and Hospital |
Forth floor OPD 401
314 B Telco Road
Chinchwad Pune Pune MAHARASHTRA |
9822057766 - vgvclinical@gmail.com |
| Dr G Sunil Kumar |
SK Clinic and Scans |
Govt. Hospital junction, Poovar,
Thiruvananthapuram
695525 Thiruvananthapuram KERALA |
8921830875 - sun786grg@gmail.com |
|
Details of Ethics Committee
Modification(s)
|
| No of Ethics Committees= 3 |
| Name of Committee |
Approval Status |
| Institutional Ethics Committee Jothydevs Diabetes Research Centre |
Approved |
| Institutional Ethics Committee Lokmanya Medical Research Centre |
Approved |
| Royal Pune Independent Ethics Commitee |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: R739||Hyperglycemia, unspecified, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Diabetone tablet along with
Cinafen plus tablet. |
One tablet of each Diabetone and Cinafen plus daily after main meal with lifestyle modifications for 90 days. |
| Comparator Agent |
Placebo |
similar placebo tablets for each Diabeton and Cinafen Plus daily after main meal with lifestyle modifications for 90 days |
|
|
Inclusion Criteria
|
| Age From |
30.00 Year(s) |
| Age To |
60.00 Year(s) |
| Gender |
Both |
| Details |
1. Male and female subjects of 30 to 60 years of age (both inclusive)
2. BMI ≥28.00-≤35 kg/m2 at screening. (Overweight to obese)
3. Hemoglobin A1c (HbA1c) ≥5.7 % and ≤6.4%.
4. Fasting Plasma Glucose (FPG) between 100-125 mg/Dl both inclusive. |
|
| ExclusionCriteria |
| Details |
1. Subjects with type 1 or type 2 diabetes mellitus (T2DM), gestational diabetes (GDM), or secondary diabetes;
2. Treatment with glucose lowering agent (s) within 90 days before screening.
3. Subjects with elevated liver enzymes AST and/or ALT >3 times of the upper normal limit
4. Subjects with abnormal renal function as measured by eGFR <45ml/min/1.73m2
5. Subjects with BMI more than 35Kg/m2
6. Subjects who had a bariatric surgery.
7. Pregnant or lactating women.
8. Smokers/Alcoholics and/or drug abusers.
9. Subjects with known history or ongoing malignancy.
10. Treatment with immunosuppressive medications in past three months.
11. Subjects suffering from major systemic illness necessitating medical care.
12. Any other reason which can affect the participation of the subject in the study as per investigator’s discretion. |
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
Case Record Numbers |
|
Blinding/Masking
|
Participant and Investigator Blinded |
|
Primary Outcome
|
| Outcome |
TimePoints |
1. HbA1c, fasting and post meal plasma glucose levels from screening to end of the study.
2. HOMA-IR score (calculated insulin resistance based on formula with fasting plasma glucose and fasting serum insulin levels) at screening and end of the study. |
Screening to end of the study |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
1. Anthropometric parameters like body weight, BMI and % body fat by impendence test at screening and end of the study.
2. Changes in lipid profile at screening and end of the study.
3. Changes in perceived stress score at screening and end of the study.
4. Changes in HRQOL-15D questionnaire score to assess quality of life at screening and end of the study. |
Screening to end of the study |
|
|
Target Sample Size
|
Total Sample Size="300" Sample Size from India="300"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
02/12/2022 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="0" Months="6" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
Nil |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Prediabetes is the earliest identifiable stage of glucose dysregulation, characterized by plasma glucose levels that are intermediate between normal glucose tolerance and diabetes. In prediabetes there is a disrupted fat metabolism and early stage of disrupted insulin regulation i.e., reduced insulin sensitivity. Obesity is the most powerful yet modifiable risk factor for diabetes. It is linked with an increased insulin demand and increased likelihood of insulin resistance leading to prediabetes or hyperinsulinemia and then ultimately T2DM. Nutritional
intervention is important for preventing diabetes, managing existing diabetes
& preventing or at least slowing, the rate of development of diabetes complications.
Dietary factors are of paramount importance in the management & prevention prediabetes.
Balancing the right amount of macronutrients & micronutrients helps us to
maintain a healthy diet & a healthy lifestyle.
Micronutrients
serve dual roles: they maintain the stabilization of the cellular structures at
their optimal levels, but their inadequacy proceeds to alternate pathways and
may cause ailments. These essential micronutrients have important physiological
implications and exhibit direct associations with diabetes mellitus. Micronutrients
are identified as vital nutrients that are required in trace amounts for
homeostasis, enzyme regulation and functioning. Macro elements, vitamins, trace
elements and organic acids are the four major classes of micronutrients. They
enhance insulin action by activating insulin receptor sites. These trace
elements play specific roles in the pathogenesis and progression of type 2
diabetes mellitus (T2DM) and the mode of action of a number of macro and trace
elements is altered in T2DM.
A
personalized approach for preventing and managing prediabetes should consider
biological and behavioral models, and embed nutrition education as part of
lifestyle diabetes prevention studies. Functional foods may provide additional
benefits in such an approach. Phytoconstituents in cinnamon such as cinnamomum aromaticum (Cassia), cinnamomum
zeylanicum, etc. have been demonstrated its effect in managing
diabetes and metabolic disorder by upregulating glucose uptake, increasing
glycogen synthesis, inhibiting glycogen breakdown, and reducing glucose
absorption in the small gut. Phytoconstituents in fenugreek namely, diosgenin,
4-hydroxyisoleucine, alkaloid and the fiber component, are the most studied
bioactive fractions of the plant, which were found to exert beneficial effects
on lowering blood glucose, glucose tolerance, insulin function, inflammatory
response, lipid profile, and liver functions. Diabetone tablets are blend of micronutrients and
cinafen plus possess standardized extracts of cinnamon and fenugreek. The
present research is an attempt to assess the efficacy & safety of Diabetone and Cinafen plus tablets in
subjects with prediabetes. With the present research we can apply the
knowledge of pharmacological benefits of micronutrients along with the clinical
trials to address the important medical issue of growing prediabetic population
to improve glycaemic control, control the disease progression and possibly to
reverse the condition. To provide appropriate and timely care to prediabetic
subjects, achieve good control of glycemia, reduce the risk of complications
related to diabetes, minimise healthcare use, and associated costs by reversing
the devastating condition and thereby improving the subjects’ quality of life,
it is necessary to begin primary translational work as soon as possible.
As
per the macronutrient recommendations for remission and prevention of Diabetes
in Asian Indians, with adjusting the proper balance of carbohydrates, protein
and fats in diet the remission, and prevention of progression to T2DM is
observed. In line with this study our hypothesis is in longer perspective,
micronutrients and phytoconstituents based supplementation will provide good
prognosis to the disease with less or no dependency on conventional
antidiabetic medication together with reduced or no side effects. Moreover,
improved glycemic control will avoid acute decompensation, delay or prevention
of microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular
complications, reduce mortality, and maintain a good quality of life. A
systematic clinical validation of the investigational products in comparison
with placebo from the present study will provide a guideline and evidence for
care givers and diabetologists to use the standardized nutrition and
phytoconstituents in their clinical practice in the management of prediabetes. |